Harbour BioMed’s IND for HBM7004 Bispecific Antibody Accepted by NMPA for Advanced Solid Tumors Following U.S. Clearance
Harbour BioMed (HKG: 2142) announced that China’s National Medical Products Administration (NMPA) has accepted its...
Others
Orionis Biosciences Secures $1.44 Billion Novartis Partnership for Molecular Glue Drug Discovery Using AI-Powered Allo-Glue Platform
Orionis Biosciences announced a multi-year strategic collaboration with global pharmaceutical leader Novartis AG (NYSE: NVS)...
GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced today a definitive agreement to acquire Nuvalent, Inc. (NASDAQ:...
Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials
Eli Lilly and Company (NYSE: LLY) announced additional positive results from pivotal Phase III trials...
AbbVie’s AQUIPTA (Atogepant) Receives European Commission Approval for Acute Migraine Treatment, Expanding Beyond Preventive Use
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...
Xtalpi’s AI Biology Spin-off INFevo Secures Tens of Millions in Angel Funding to Build Virtual Cell System for Drug Discovery
Xtalpi Inc. (HKG: 2228) announced that its AI biology subsidiary INFevo has completed an angel...
CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus
CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China’s...
Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 – Novel siRNA Antithrombotic for Coronary Artery Disease
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II...
Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis
Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has...
CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage
CanSino Biologics Inc. (HKG: 6185) announced the initiation of its Phase I/II clinical study for...
Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
A federal jury in the U.S. District Court for the District of Massachusetts returned a...
UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis
UCB (EBR: UCB) announced today Week 16 data from the BE BOLD Phase III clinical...
Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs – Patients Bear Excess Costs Above Winning Prices
The Shanghai Municipal Healthcare Security Bureau issued the “Notice on Optimizing Payment Coordination for the...
Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s...
Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development
Porton Advanced Solutions and Dark Horse Consulting Group (“DHCG”) announced on May 12, 2026, the...
Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition
Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of €13.405 billion (USD 15.73 billion),...
Cue Biopharma Licenses Ascendant-221 Anti-IgE Antibody for $691.5M Deal, Excluding Greater China
Cue Biopharma Inc. (NASDAQ: CUE) announced an exclusive licensing agreement with Ascendant Health Sciences Ltd.,...
GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai...
Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced it has received marketing approval from China’s...
Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline
Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus...